Sarepta Therapeutics (NASDAQ: SRPT) CEO Douglas Ingram to retire by 2026

Rhea-AI Filing Summary

Sarepta Therapeutics, Inc. reported that Chief Executive Officer Douglas Ingram has decided to retire. On February 25, 2026, he informed the company that he plans to step down by the end of 2026 or once a successor is appointed.

The company has begun a formal search process, considering both internal and external candidates to identify its next CEO. This filing does not discuss changes to the company’s strategy or operations, focusing solely on the planned leadership transition timeline.

Insights

Corporate governance analyst

Planned CEO retirement initiates an orderly leadership transition.

Sarepta Therapeutics disclosed that CEO Douglas Ingram plans to retire by the end of 2026 or upon appointment of his successor. The company has already started a search across internal and external candidates, indicating intent to manage succession in a structured way.

The disclosure frames this as a retirement decision, not an abrupt departure, which generally suggests continuity while the search proceeds. Actual strategic impact will depend on who is ultimately selected as the next CEO and how that person shapes future priorities.

The key milestone to watch is the announcement of the new CEO, which will clarify the board’s chosen direction and offer more insight into potential shifts in leadership style and long-term plans once the transition occurs.

8-K Event Classification

Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

1 item

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Understanding 8-K Material Events →

0000873303false00008733032026-02-252026-02-25

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 25, 2026

Sarepta Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-14895	93-0797222
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
215 First Street
Cambridge, Massachusetts				02142
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: (617) 274-4000

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.0001 par value per share		SRPT		Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On February 25, 2026, Douglas Ingram notified Sarepta Therapeutics, Inc. (the “Company”) of his decision to retire as Chief Executive Officer by the end of 2026 or upon the appointment of his replacement. The Company has commenced a search of internal and external candidates for Mr. Ingram’s replacement.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			Sarepta Therapeutics, Inc.
Date:	February 25, 2026	By:	/s/ Cristin L. Rothfuss
			Cristin L. Rothfuss Executive Vice President, General Counsel

FAQ

What leadership change did Sarepta Therapeutics (SRPT) disclose in this 8-K?

Sarepta Therapeutics disclosed that Chief Executive Officer Douglas Ingram has decided to retire. He plans to step down by the end of 2026 or when a replacement is appointed, signaling a planned and orderly leadership transition rather than an abrupt change.

When will Sarepta Therapeutics CEO Douglas Ingram retire?

Douglas Ingram plans to retire as CEO by the end of 2026 or upon the appointment of his successor, whichever comes first. This timeframe allows the board and company sufficient time to run a thorough search and manage an organized leadership handover.

Has Sarepta Therapeutics started searching for a new CEO?

Yes, Sarepta Therapeutics has commenced a search process for a new Chief Executive Officer. The company is considering both internal and external candidates, aiming to identify a successor to Douglas Ingram ahead of his planned retirement by the end of 2026.

Does the Sarepta Therapeutics 8-K mention changes to company strategy?

The 8-K focuses on Douglas Ingram’s planned retirement as CEO and the search for his replacement. It does not describe any specific changes to Sarepta Therapeutics’ business strategy, operations, or financial guidance associated with this leadership transition disclosure.

What SEC item does the Sarepta Therapeutics (SRPT) filing relate to?

The disclosure falls under Item 5.02, which addresses departures and appointments of directors or certain officers and compensatory arrangements. Here, Sarepta Therapeutics reports CEO Douglas Ingram’s decision to retire and the initiation of a CEO succession search process.

Filing Exhibits & Attachments

1 document

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 23.3 KB